An observational study in Ocular Surface Disease, Inflammatory Disease and Retinal Disease, sponsored by Dan Chen. Recruiting at 1 site in China. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Dan Chen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Retinal Diseases with a site in China — 12 open to participants now, 14 under way, 1 of them phase 3. Retinal Diseases · China.
Among the 29 studies in Retinal Diseases with a site in China, this one is the 7th largest by planned enrollment of the 17 observational ones that give a count, is one of 4 that started in 2025, is one of 17 observational ones, reaches primary completion later than 12 of the 13 other live ones, and was the 27th registered.
333 studies on the registry are indexed under Retinal Diseases; 59 are open to participants now.
Browse Retinal Diseases studies →12 of the 29 studies in Retinal Diseases with a site in China are open now. Recruiting first, the newest first:
InnoVec Biotherapeutics Inc. · Sites in China
Ages 50+
VeonGen Therapeutics GmbH · Sites in China
Ages 6+
Beijing Tongren Hospital · Sites in China
Ages 1–100
Beijing Tongren Hospital · Sites in China
Ages 50–75
Sun Yat-sen University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 44 Retinal Diseases studies recruiting now, 30 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 16 take children under 18; 19 take healthy volunteers.
This study: 3 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 1
First in 2010; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 3,000 is above the median of 200 across 118 observational studies indexed under Retinal Diseases.
Median enrollment 35 across the 11 interventional studies, 2,000 across the 17 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 29 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dan Chen as lead sponsor.
Dan Chen has 1 study filed under Retinal Diseases — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Retinal Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Through a systematic observational study, the intrinsic connections and patterns between the occurrence and development of common blinding retinal diseases such as diabetic retinopathy, pathological myopia, and age-related macular degeneration and the changes in fine parameters of the anterior structure of the eye are deeply explored. To achieve this goal, investigators will adopt cutting-edge multimodal imaging technology to simultaneously collect precise data from ocular surface and fundus of participants. By integrating and analyzing these multi-dimensional information from different parts of the same eye, investigators will build a high-quality and standardized ocular surface-fundus associated image database. This database not only aims to reveal potential ocular surface biomarkers that can be used for early warning or auxiliary diagnosis, but also lays a solid data foundation for the future development of artificial intelligence-assisted diagnostic tools and the establishment of a brand-new ocular surface-fundus integrated diagnosis and treatment assessment model.
The study population includes patients with both inflammatory and non-inflammatory ocular diseases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Tear Break-Up Time
The time from the last complete blink to the appearance of the first dry spot on the cornea.
Time frame: Baseline and within 30 days post-procedure
Dry Eye Questionnaire-5
The DEQ-5 comprises five items assessing the frequency of dryness, discomfort, and watery eyes, as well as the late-day intensity of dryness and discomfort. Patients rate each item on a 0-4 or 0-5 scale, and the total score is summed. Higher scores indicate greater dry eye symptom severity.
Time frame: Baseline and within 30 days post-procedure
Meibomian Gland Dropout
Meibomian gland dropout will be measured using infrared meibography.
Time frame: Baseline and within 30 days post-procedure
Blink Rate
Blink rate will be measured using a video recording system under natural blinking conditions. The number of complete blinks and incomplete blinks per minute will be counted separately.
Time frame: Baseline and within 30 days post-procedure
Lipid Layer Thickness
Lipid layer thickness refers to the thickness of the lipid layer of the tear film, which is the outermost layer of the precorneal tear film.
Time frame: Baseline and within 30 days post-procedure
Tear Meniscus Height
Tear meniscus height refers to the vertical height of the tear volume accumulated along the lower eyelid margin.
Time frame: Baseline and within 30 days post-procedure
Central Subfield Thickness
Central subfield thickness refers to the thickness of the retina at the fovea.
Time frame: Baseline and within 30 days post-procedure
Subfoveal Choroidal Thickness
Subfoveal choroidal thickness refers to the thickness of the choroid directly beneath the fovea.
Time frame: Baseline and within 30 days post-procedure
Subretinal Fluid
Subretinal fluid refers to fluid accumulation in the potential space between the neurosensory retina and the retinal pigment epithelium.
Time frame: Baseline and within 30 days post-procedure
Intraretinal Fluid
Intraretinal fluid refers to fluid accumulation within the retinal layers, typically appearing as cystoid spaces.
Time frame: Baseline and within 30 days post-procedure
Pigment Epithelial Detachment Height
Pigment epithelial detachment height refers to the maximal vertical height of separation of the retinal pigment epithelium from the underlying Bruch's membrane.
Time frame: Baseline and within 30 days post-procedure
Started Nov 2025 (actual). Primary completion is estimated for Feb 2030, 51 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.